Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 3
1947 2
1948 1
1949 4
1950 3
1951 2
1952 3
1953 2
1954 5
1955 1
1956 2
1957 3
1958 1
1960 2
1961 2
1963 2
1964 2
1965 4
1966 5
1967 4
1968 5
1969 7
1970 12
1971 16
1972 14
1973 16
1974 16
1975 104
1976 100
1977 102
1978 86
1979 98
1980 98
1981 135
1982 124
1983 161
1984 178
1985 182
1986 203
1987 206
1988 215
1989 278
1990 322
1991 327
1992 362
1993 416
1994 472
1995 512
1996 633
1997 698
1998 667
1999 721
2000 786
2001 807
2002 930
2003 947
2004 1024
2005 1259
2006 1328
2007 1464
2008 1526
2009 1586
2010 1740
2011 2072
2012 2214
2013 2383
2014 2577
2015 2631
2016 2511
2017 2522
2018 2469
2019 2429
2020 2450
2021 2540
2022 2276
2023 1965
2024 806

Text availability

Article attribute

Article type

Publication date

Search Results

47,405 results

Results by year

Filters applied: . Clear all
Page 1
Non-invasive diagnosis of advanced fibrosis and cirrhosis.
Sharma S, Khalili K, Nguyen GC. Sharma S, et al. World J Gastroenterol. 2014 Dec 7;20(45):16820-30. doi: 10.3748/wjg.v20.i45.16820. World J Gastroenterol. 2014. PMID: 25492996 Free PMC article. Review.
On the whole, radiologic and serum markers of fibrosis correlate well with biopsy scores, especially when excluding cirrhosis or excluding fibrosis. ...
On the whole, radiologic and serum markers of fibrosis correlate well with biopsy scores, especially when excluding cirrhosis or excl …
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, Stefanescu H, Ma MM, Mandorfer M, Mergeay-Fabre M, Procopet B, Schwabl P, Ferlitsch A, Semmler G, Berzigotti A, Tsochatzis E, Bureau C, Reiberger T, Bosch J, Abraldes JG, Genescà J. Pons M, et al. Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994. Am J Gastroenterol. 2021. PMID: 33982942
RESULTS: A total of 836 patients with hepatitis C (n = 358), nonalcoholic steatohepatitis (NASH, n = 248), alcohol use (n = 203), and hepatitis B (n = 27) were evaluated. ...LSM 25 kPa was the best cutoff to rule in CSPH in alcoholic liver disease, chronic hepati …
RESULTS: A total of 836 patients with hepatitis C (n = 358), nonalcoholic steatohepatitis (NASH, n = 248), alcohol use (n = 203), and …
Diagnostic histochemistry in hepatic pathology.
Iezzoni JC. Iezzoni JC. Semin Diagn Pathol. 2018 Nov;35(6):381-389. doi: 10.1053/j.semdp.2018.10.003. Epub 2018 Oct 16. Semin Diagn Pathol. 2018. PMID: 30409459 Review.
The results contribute to the diagnosis of acute and chronic hepatitis, submassive necrosis, venous outflow obstruction, steatohepatitis, and cirrhosis. ...
The results contribute to the diagnosis of acute and chronic hepatitis, submassive necrosis, venous outflow obstruction, steatohepati …
HCC Risk Scores: Useful or Not?
Sherman M. Sherman M. Semin Liver Dis. 2017 Nov;37(4):287-295. doi: 10.1055/s-0037-1607452. Epub 2017 Dec 22. Semin Liver Dis. 2017. PMID: 29272891 Review.
Specific models have been developed for hepatitis B before and on treatment, for hepatitis C before and after treatment, and for cirrhosis in general. ...Some models can only be applied to patients coming from the population in which the score was developed ( …
Specific models have been developed for hepatitis B before and on treatment, for hepatitis C before and after treatment, and f …
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. Wai CT, et al. Hepatology. 2003 Aug;38(2):518-26. doi: 10.1053/jhep.2003.50346. Hepatology. 2003. PMID: 12883497 Free article.
Information on the stage of liver fibrosis is essential in managing chronic hepatitis C (CHC) patients. However, most models for predicting liver fibrosis are complicated and separate formulas are needed to predict significant fibrosis and cirrhosis. ...Using …
Information on the stage of liver fibrosis is essential in managing chronic hepatitis C (CHC) patients. However, most models for p …
Diagnostic and prognostic scoring systems for autoimmune hepatitis: a review.
Ducazu O, Degroote H, Geerts A, Hoorens A, Schouten J, Van Vlierberghe H, Verhelst X. Ducazu O, et al. Acta Gastroenterol Belg. 2021 Jul-Sep;84(3):487-495. doi: 10.51821/84.3.014. Acta Gastroenterol Belg. 2021. PMID: 34599574 Free article. Review.
Concerning these overlap syndromes, the Paris criteria show a higher diagnostic accuracy compared to the scoring systems for AIH. Presently, no clinical prognostic scoring systems are available. However, a first system based on response to treatment ac …
Concerning these overlap syndromes, the Paris criteria show a higher diagnostic accuracy compared to the scoring systems for A …
Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients.
Lee HW, Ahn SH. Lee HW, et al. World J Gastroenterol. 2016 Oct 7;22(37):8314-8321. doi: 10.3748/wjg.v22.i37.8314. World J Gastroenterol. 2016. PMID: 27729738 Free PMC article. Review.
Several HCC risk scores based on risk factors such as cirrhosis, age, male gender, and high viral load have been used, and have negative predictive values of 95%. Most of these have been derived from, and internally validated in, treatment-naive Asian CHB patients. …
Several HCC risk scores based on risk factors such as cirrhosis, age, male gender, and high viral load have been used, and have negat …
Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management.
Czaja AJ. Czaja AJ. Expert Rev Gastroenterol Hepatol. 2018 Jun;12(6):547-564. doi: 10.1080/17474124.2018.1453356. Epub 2018 Mar 20. Expert Rev Gastroenterol Hepatol. 2018. PMID: 29540068 Review.
Autoimmune hepatitis lacks a quantifiable biomarker that is close to its pathogenic mechanisms and that accurately reflects inflammatory activity, correlates with treatment response, and ensures inactive disease before treatment withdrawal. Areas covered: Micro-ribonucleic …
Autoimmune hepatitis lacks a quantifiable biomarker that is close to its pathogenic mechanisms and that accurately reflects inflammat …
Chronic viral hepatitis: the histology report.
Guido M, Mangia A, Faa G; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Guido M, et al. Dig Liver Dis. 2011 Mar;43 Suppl 4:S331-43. doi: 10.1016/S1590-8658(11)60589-6. Dig Liver Dis. 2011. PMID: 21459339
Several scoring systems have been proposed for grading and staging chronic viral hepatitis and there is no a general consensus on the best system to be used in the daily practice. All scoring systems have their drawbacks and all may be affected …
Several scoring systems have been proposed for grading and staging chronic viral hepatitis and there is no a general co …
Evidence of bias in randomized clinical trials of hepatitis C interferon therapies.
Tinè F, Attanasio M, Muggeo VMR, Crainiceanu CM. Tinè F, et al. Clin Trials. 2017 Oct;14(5):483-488. doi: 10.1177/1740774517715447. Epub 2017 Jul 1. Clin Trials. 2017. PMID: 28670909 Review.
Using results from published trials, we analyzed and compared the treatment effect of hepatitis C antiviral interferon therapies experimental or control. ...We discuss several factors related to design and conduct of hepatitis C trials as potential explanations of t …
Using results from published trials, we analyzed and compared the treatment effect of hepatitis C antiviral interferon therapies expe …
47,405 results
You have reached the last available page of results. Please see the User Guide for more information.